Evergrowth BioHealthcare Capital, managed by Evergrowth BioHealthcare Advisors, is a Delaware-incorporated biotech hedge fund with a specialized focus on binary event forecasting—key milestones such as FDA approvals or major clinical data releases that often drive significant stock price movements.
Our fund strategically targets clinical-stage and early product-stage public biotech equities. With a commitment to outperforming market benchmarks like the Dow Jones Industrial Average (INDU), Nasdaq Biotechnology Index (NBI), and S&P 500 (SPY) over the long term, we strive to deliver exceptional returns for our investors while supporting transformative advancements in biotechnology.
Why Choose Evergrowth BioHealthcare Capital?
I.
Deep Understanding of Biotech Industry
Our team of experienced professionals brings deep expertise in the biotech industry, empowering us to identify and capitalize on high-potential investment opportunities in innovative biotech companies.
II.
DData-Driven Approach
We utilize a data-driven approach to identify and evaluate investment opportunities in the biotech sector, providing our clients with a diversified portfolio and competitive returns.
III.
Expertise in Biotech and Finance
By integrating our expertise in biotechnology and finance, we provide a distinctive investment approach designed to harness the potential of medical breakthroughs while delivering compelling returns for our clients.
Investment Terms
Key investment terms for our fund include a minimum investment of $50,000, a 2% management fee, a 20% performance fee, a three-year lockup period (1095 days), and a 30-day withdrawal notice. As an open fund, we welcome potential investors and are open to discussing customized terms to meet specific needs.
Service Providers
We collaborate with top-tier partners to ensure robust operations and compliance. Tax and auditing services are provided by Spicer Jeffries LLP, a renowned Colorado-based firm specializing in asset management. Our hedge fund administration is managed by Repool Inc., an innovative company based in New York City. For legal expertise, we rely on Berger McDermott LLP, a Delaware law firm specializing in hedge fund management.
Management Team
Our Board of Directors is led by Dr. Harvey Tran, who also serves as CEO and Chief Investment Officer, and Mr. David Newman. Supporting the leadership, our management team includes a Medical/Scientific Advisory Board and a Technology/Business Development Advisory Board, ensuring a well-rounded and expert-driven approach to our fund’s operations and strategies.
Board of Directors
Dr. Harvey Tran leads the implementation and execution of the Fund’s investment strategy. A physician executive, scientist, mentor, and entrepreneur, Dr. Tran founded Integrated BioSci Investing in 2017, a biotech investment research and consulting firm.
Since 2019, he has consulted for pharmaceutical companies, providing strategic guidance on investor relations and medical expertise. In 2020, he founded High Performance Healthcare, focusing on acquiring home healthcare agencies, serving as its CEO and Board member. Dr. Tran is also a member of Spru Ventures, a venture capital group specializing in alternative investments, and has held leadership roles, including Vice President of the Canterbury Homeowners Association.
Dr. Tran earned his MS from the prestigious Columbia University College of Physicians and Surgeons in New York City and completed his MD at The Brody School of Medicine in 2013.
Mr. David Newman is a securities lawyer with over 30 years of enforcement and regulatory expertise. Currently in private practice, he also serves as a consultant with the Bates Group.
From 1999 to 2022, Mr. Newman was Counsel for the Financial Industry Regulatory Authority’s (FINRA) Enforcement Department, where he managed all aspects of enforcement cases, including investigations, settlement negotiations, and litigation. Prior to this, he served as Trial Counsel and Special Counsel with the Securities and Exchange Commission (SEC) from 1990 to 1999, handling investigations and litigation of federal securities law violations. Additionally, Mr. Newman dedicated 28 years of service as a Judge Advocate in the United States Air Force.
Mr. Newman holds a BA from Boston University and a JD from New York Law School.
Executive Leadership
Medical and Scientific Advisory Board
Technology & Business Development Advisory Board
Fund Founders
